|
1
|
McGettigan S: Dabrafenib: A new therapy
for use in BRAF-mutated metastatic melanoma. J Adv Pract Oncol.
5:211–215. 2014.PubMed/NCBI
|
|
2
|
Lens MB and Dawes M: Global perspectives
of contemporary epidemiological trends of cutaneous malignant
melanoma. Br J Dermatol. 150:179–185. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rigel DS, Russak J and Friedman R: The
evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA
Cancer J Clin. 60:301–316. 2010. View Article : Google Scholar
|
|
4
|
Menaa F: Latest approved therapies for
metastatic melanoma: What comes next? J Skin Cancer.
2013:7352822013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Graham B and Gibson SB: The two faces of
NFkappaB in cell survival responses. Cell Cycle. 4:1342–1345. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kiernan R, Brès V, Ng RWM, Coudart MP, El
Messaoudi S, Sardet C, Jin DY, Emiliani S and Benkirane M:
Post-activation turn-off of NF-κB-dependent transcription is
regulated by acetylation of p65. J Biol Chem. 278:2758–2766. 2003.
View Article : Google Scholar
|
|
7
|
Doyle SL and O’Neill LA: Toll-like
receptors: From the discovery of NFkappaB to new insights into
transcriptional regulations in innate immunity. Biochem Pharmacol.
72:1102–1113. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Perkins ND and Gilmore TD: Good cop, bad
cop: The different faces of NF-kappaB. Cell Death Differ.
13:759–772. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kashani-Sabet M, Liu Y, Fong S, Desprez
PY, Liu S, Tu G, Nosrati M, Handumrongkul C, Liggitt D, Thor AD, et
al: Identification of gene function and functional pathways by
systemic plasmid-based ribozyme targeting in adult mice. Proc Natl
Acad Sci USA. 99:3878–3883. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kashani-Sabet M, Shaikh L, Miller JR III,
Nosrati M, Ferreira CM, Debs RJ and Sagebiel RW: NF-kappa B in the
vascular progression of melanoma. J Clin Oncol. 22:617–623. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Munshi A, Kurland JF, Nishikawa T, Chiao
PJ, Andreeff M and Meyn RE: Inhibition of constitutively activated
nuclear factor-kappaB radiosensitizes human melanoma cells. Mol
Cancer Ther. 3:985–992. 2004.PubMed/NCBI
|
|
12
|
Ichikawa H, Takada Y, Shishodia S,
Jayaprakasam B, Nair MG and Aggarwal BB: Withanolides potentiate
apoptosis, inhibit invasion, and abolish osteoclastogenesis through
suppression of nuclear factor-kappaB (NF-kappaB) activation and
NF-kappaB-regulated gene expression. Mol Cancer Ther. 5:1434–1445.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fuster MM and Esko JD and Esko JD: The
sweet and sour of cancer: Glycans as novel therapeutic targets. Nat
Rev Cancer. 5:526–542. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weston BW, Nair RP, Larsen RD and Lowe JB:
Isolation of a novel human alpha (1,3)fucosyltransferase gene and
molecular comparison to the human Lewis blood group alpha (1,3/1,4)
fucosyltransferase gene. Syntenic, homologous, nonallelic genes
encoding enzymes with distinct acceptor substrate specificities. J
Biol Chem. 267:4152–4160. 1992.PubMed/NCBI
|
|
15
|
Weston BW, Smith PL, Kelly RJ and Lowe JB:
Molecular cloning of a fourth member of a human alpha
(1,3)fucosyltransferase gene family. Multiple homologous sequences
that determine expression of the Lewis x, sialyl Lewis x, and
difucosyl sialyl Lewis x epitopes. J Biol Chem. 267:24575–24584.
1992.PubMed/NCBI
|
|
16
|
Petretti T, Schulze B, Schlag PM and
Kemmner W: Altered mRNA expression of glycosyltransferases in human
gastric carcinomas. Biochim Biophys Acta. 1428:209–218. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ito H, Hiraiwa N, Sawada-Kasugai M,
Akamatsu S, Tachikawa T, Kasai Y, Akiyama S, Ito K, Takagi H and
Kannagi R: Altered mRNA expression of specific molecular species of
fucosyl- and sialyl-transferases in human colorectal cancer
tissues. Int J Cancer. 71:556–564. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ogawa J, Inoue H and Koide S: Expression
of alpha-1,3-fucosyltransferase type IV and VII genes is related to
poor prognosis in lung cancer. Cancer Res. 56:325–329.
1996.PubMed/NCBI
|
|
19
|
Yang X, Zhang Z, Jia S, Liu Y, Wang X and
Yan Q: Overexpression of fucosyltransferase IV in A431 cell line
increases cell proliferation. Int J Biochem Cell Biol.
39:1722–1730. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang X, Liu S and Yan Q: Role of
fucosyltransferase IV in epithelial-mesenchymal transition in
breast cancer cells. Cell Death Dis. 4:e7352013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang X, Liu Y, Liu J, Wang X and Yan Q:
Cyclophosphamide-induced apoptosis in A431 cells is inhibited by
fucosyltransferase IV. J Cell Biochem. 112:1376–1383. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan HD, Quan HY, Zhang Y, Kim SH and
Chung SH: 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon
cancer cells is associated with AMPK signaling pathway. Mol Med
Rep. 3:825–831. 2010.
|
|
23
|
Park EH, Kim YJ, Yamabe N, Park SH, Kim
HK, Jang HJ, Kim JH, Cheon GJ, Ham J and Kang KS: Stereospecific
anticancer effects of ginsenoside Rg3 epimers isolated from
heat-processed American ginseng on human gastric cancer cell. J
Ginseng Res. 38:22–27. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim SM, Lee SY, Cho JS, Son SM, Choi SS,
Yun YP, Yoo HS, Yoon Y, Oh KW, Han SB, et al: Combination of
ginsenoside Rg3 with docetaxel enhances the susceptibility of
prostate cancer cells via inhibition of NF-kappaB. Eur J Pharmacol.
631:1–9. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee CK, Park KK, Chung AS and Chung WY:
Ginsenoside Rg3 enhances the chemosensitivity of tumors to
cisplatin by reducing the basal level of nuclear factor erythroid
2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone
oxido-reductase-1 and prevents normal tissue damage by scavenging
cisplatin-induced intracellular reactive oxygen species. Food Chem
Toxicol. 50:2565–2574. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu Y, Zhang C, Liu L and Li X: Hepatic
arterial administration of ginsenoside Rg3 and transcatheter
arterial embolization for the treatment of VX2 liver carcinomas.
Exp Ther Med. 5:761–766. 2013.PubMed/NCBI
|
|
27
|
Shan X, Aziz F, Tian LL, Wang XQ, Yan Q
and Liu JW: Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation
inhibits melanoma cell proliferation by decreasing FUT4/LeY
expression. Int J Oncol. 46:1667–1676. 2015.PubMed/NCBI
|
|
28
|
Wang JH, Nao JF, Zhang M and He P:
20(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer
HO-8910 cells through PI3K/Akt and XIAP pathways. Tumour Biol.
35:11985–11994. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim BM, Kim DH, Park JH, Surh YJ and Na
HK: Ginsenoside Rg3 inhibits constitutive activation of NF-κB
signaling in human breast cancer (MDA-MB-231) cells: ERK and Akt as
potential upstream targets. J Cancer Prev. 19:23–30. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Z, Sun P, Liu J, Fu L, Yan J, Liu Y,
Yu L, Wang X and Yan Q: Suppression of FUT1/FUT4 expression by
siRNA inhibits tumor growth. Biochim Biophys Acta. 1783:287–296.
2008. View Article : Google Scholar
|
|
31
|
Yang X, Wang J, Liu S and Yan Q: HSF1 and
Sp1 regulate FUT4 gene expression and cell proliferation in breast
cancer cells. J Cell Biochem. 115:168–178. 2014. View Article : Google Scholar
|
|
32
|
Hongyan L, Shaoming T and Qiu Y:
Correlation between FUT4 expression and its promoter methylation in
HaCaT cells. Yi Chuan. 37:48–54. 2015.PubMed/NCBI
|
|
33
|
Kim MK, Jeon YK, Woo JK, Choi Y, Choi DH,
Kim YH and Kim CW: The C-terminal region of Bfl-1 sensitizes
non-small cell lung cancer to gemcitabine-induced apoptosis by
suppressing NF-κB activity and down-regulating Bfl-1. Mol Cancer.
10:982011. View Article : Google Scholar
|
|
34
|
Brandi G, Pantaleo MA, Biasco G and
Paterini P: Activated NF-κB in colorectal cancer: Predictive or
prognostic factor? J Clin Oncol. 26:1388–1389; author reply
1389–1390. 2008. View Article : Google Scholar
|
|
35
|
Richmond A: NF-κB, chemokine gene
transcription and tumour growth. Nat Rev Immunol. 2:664–674. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Karin M, Cao Y, Greten FR and Li ZW:
NF-kappaB in cancer: From innocent bystander to major culprit. Nat
Rev Cancer. 2:301–310. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Melnikova VO and Bar-Eli M:
Transcriptional control of the melanoma malignant phenotype. Cancer
Biol Ther. 7:997–1003. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Heon Seo K, Ko HM, Kim HA, Choi JH, Jun
Park S, Kim KJ, Lee HK and Im SY: Platelet-activating factor
induces up-regulation of antiapoptotic factors in a melanoma cell
line through nuclear factor-kappaB activation. Cancer Res.
66:4681–4686. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cheng L, Luo S, Jin C, Ma H, Zhou H and
Jia L: FUT family mediates the multidrug resistance of human
hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell
Death Dis. 4:e9232013. View Article : Google Scholar : PubMed/NCBI
|
